Citation: | JIA Chenhao, WU Meiqi, GUO Ruijie, NI Jun, CUI Ruixue. Comparative Study of 18F-FDG PET/CT Metabolic Alteration Patterns in Cerebral Amyloid Angiopathy and Alzheimer's Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 263-269. DOI: 10.12290/xhyxzz.2021-0693 |
[1] |
Boulouis G, Charidimou A, Greenberg SM. Sporadic Cerebral Amyloid Angiopathy: Pathophysiology, Neuroimag-ing Features, and Clinical Implications[J]. Semin Neurol, 2016, 36: 233-243. DOI: 10.1055/s-0036-1581993
|
[2] |
Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy[J]. Brain, 2017, 140: 1829-1850. DOI: 10.1093/brain/awx047
|
[3] |
Akers C, Acosta LMY, Considine C, et al. Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy[J]. Curr Neurol Neurosci Rep, 2019, 19: 64. DOI: 10.1007/s11910-019-0981-4
|
[4] |
Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy[J]. Neurology, 2010, 74: 1346-1350. DOI: 10.1212/WNL.0b013e3181dad605
|
[5] |
Greenberg SM, Charidimou A. Diagnosis of Cerebral Amy-loid Angiopathy: Evolution of the Boston Criteria[J]. Stroke, 2018, 49: 491-497. DOI: 10.1161/STROKEAHA.117.016990
|
[6] |
Charidimou A, Farid K, Baron JC. Amyloid-PET in sporadic cerebral amyloid angiopathy: A diagnostic accuracy meta-analysis[J]. Neurology, 2017, 89: 1490-1498. DOI: 10.1212/WNL.0000000000004539
|
[7] |
Charidimou A, Farid K, Tsai HH, et al. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 410-417. DOI: 10.1136/jnnp-2017-316851
|
[8] |
Farid K, Charidimou A, Baron JC. Amyloid positron emis-sion tomography in sporadic cerebral amyloid angiopathy: A systematic critical update[J]. Neuroimage Clin, 2017, 15: 247-263. DOI: 10.1016/j.nicl.2017.05.002
|
[9] |
Planton M, Saint-Aubert L, Raposo N, et al. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study[J]. J Alzheimers Dis, 2020, 73: 1607-1614. DOI: 10.3233/JAD-190625
|
[10] |
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impair-ment, Alzheimer's disease, and other dementias[J]. J Nucl Med, 2008, 49: 390-398. DOI: 10.2967/jnumed.107.045385
|
[11] |
Smailagic N, Vacante M, Hyde C, et al. 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2015, 1: Cd010632.
|
[12] |
Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prod-romal AD[J]. Neuroimage Clin, 2021, 31: 102754. DOI: 10.1016/j.nicl.2021.102754
|
[13] |
Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 1497-1508. DOI: 10.1007/s00259-018-4039-7
|
[14] |
Bergeret S, Queneau M, Rodallec M, et al. Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study[J]. Stroke, 2021, 52: 1478-1482. DOI: 10.1161/STROKEAHA.120.032905
|
[15] |
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13: 614-629. DOI: 10.1016/S1474-4422(14)70090-0
|
[16] |
Bergeret S, Queneau M, Rodallec M, et al. [(18) F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease[J]. Eur J Neurol, 2021, 28: 1511-1519. DOI: 10.1111/ene.14743
|
[17] |
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. Lancet, 2021, 397: 1577-1590. DOI: 10.1016/S0140-6736(20)32205-4
|
[18] |
Gatti L, Tinelli F, Scelzo E, et al. Understanding the Pathophysiology of Cerebral Amyloid Angiopathy[J]. Int J Mol Sci, 2020, 21: 3435. DOI: 10.3390/ijms21103435
|
[19] |
Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly[J]. Ann Neurol, 2011, 70: 871-880. DOI: 10.1002/ana.22516
|
[20] |
Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. Ⅱ. The distribution of amyloid vascular changes[J]. Stroke, 1983, 14: 924-928. DOI: 10.1161/01.STR.14.6.924
|
[21] |
Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review[J]. BMC Neurol, 2009, 9: 3. DOI: 10.1186/1471-2377-9-3
|
[22] |
Samuraki M, Matsunari I, Yoshita M, et al. Cerebral Amyloid Angiopathy-Related Microbleeds Correlate with Glucose Metabolism and Brain Volume in Alzheimer's Disease[J]. J Alzheimers Dis, 2015, 48: 517-528. DOI: 10.3233/JAD-150274
|
[23] |
Farid K, Hong YT, Aigbirhio FI, et al. Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?[J]. PLoS One, 2015, 10: e0139926. DOI: 10.1371/journal.pone.0139926
|
[24] |
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers[J]. Lancet Neurol, 2017, 16: 661-676. DOI: 10.1016/S1474-4422(17)30159-X
|
[25] |
Tomonaga M. Cerebral amyloid angiopathy in the elderly[J]. J Am Geriatr Soc, 1981, 29: 151-157. DOI: 10.1111/j.1532-5415.1981.tb01757.x
|
1. |
徐晓霞,朱葛敏,赵瑞. 阿尔茨海默病患者血清Ghrelin的表达水平及临床意义. 川北医学院学报. 2024(02): 169-172 .
![]() | |
2. |
沙宇惠,倪俊. 脑淀粉样血管病的分子影像研究进展. 中华神经科杂志. 2023(08): 932-938 .
![]() |